Aquestive Therapeutics Inc.

3.58-0.1800-4.79%Vol 203.72K1Y Perf -30.33%
Jul 23rd, 2021 16:00 DELAYED
BID3.62 ASK3.74
Open3.77 Previous Close3.76
Pre-Market- After-Market-
 - -  - -%
Target Price
17.00 
Analyst Rating
Strong Buy 1.00
Potential %
374.86 
Finscreener Ranking
★★★     49.14
Insiders Trans % 3/6/12 mo.
-/-100/-100 
Value Ranking
★+     45.26
Insiders Value % 3/6/12 mo.
-/-100/-100 
Growth Ranking
★★+     47.70
Insiders Shares Cnt. % 3/6/12 mo.
-/-100/-100 
Income Ranking
 —    -
Market Cap131.00M 
Earnings Rating
Buy
Price Range Ratio 52W %
6.51 
Earnings Date
3rd Aug 2021

Today's Price Range

3.553.77

52W Range

3.179.47

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
7.83%
1 Month
-17.13%
3 Months
-12.90%
6 Months
-36.86%
1 Year
-30.33%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
AQST3.58-0.1800-4.79
AAPL148.561.76001.20
GOOG2 756.3289.75003.37
MSFT289.673.53001.23
XOM57.04-0.0700-0.12
WFC44.59-0.4400-0.98
JNJ171.791.81001.06
FB369.7918.60005.30
GE12.710.01000.08
JPM150.64-0.2900-0.19
ProfitabilityValueIndustryS&P 500US Markets
75.00
-77.80
-71.00
-74.10
-91.51
RevenueValueIndustryS&P 500US Markets
26.53M
0.73
-19.37
-
Earnings HistoryEstimateReportedSurprise %
Q01 2021-0.44-0.416.82
Q04 2020-0.46-0.60-30.43
Q03 2020-0.50-0.492.00
Q02 2020-0.43-0.0783.72
Q01 2020-0.52-0.495.77
Q04 2019-0.45-0.48-6.67
Q03 2019-0.78-0.5430.77
Q02 2019-0.67-0.82-22.39
Earnings Per EndEstimateRevision %Trend
6/2021 QR-0.422.33Positive
9/2021 QR-0.444.35Positive
12/2021 FY-1.702.86Positive
12/2022 FY-1.14-3.64Negative
Next Report Date3rd Aug 2021
Estimated EPS Next Report-0.42
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume203.72K
Shares Outstanding36.59M
Trades Count1.43K
Dollar Volume4.88M
Avg. Volume769.75K
Avg. Weekly Volume524.30K
Avg. Monthly Volume643.28K
Avg. Quarterly Volume583.51K

Aquestive Therapeutics Inc. (NASDAQ: AQST) stock closed at 3.58 per share at the end of the most recent trading day (a -4.79% change compared to the prior day closing price) with a volume of 204.39K shares and market capitalization of 131.00M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 232 people. Aquestive Therapeutics Inc. CEO is Keith J. Kendall.

The one-year performance of Aquestive Therapeutics Inc. stock is -30.33%, while year-to-date (YTD) performance is -33.08%. AQST stock has a five-year performance of %. Its 52-week range is between 3.17 and 9.47, which gives AQST stock a 52-week price range ratio of 6.51%

Aquestive Therapeutics Inc. currently has a PE ratio of -2.10, a price-to-book (PB) ratio of 14.15, a price-to-sale (PS) ratio of 4.58, a price to cashflow ratio of 38.20, a PEG ratio of 2.32, a ROA of -85.32%, a ROC of -107.70% and a ROE of 148.50%. The company’s profit margin is -91.51%, its EBITDA margin is -71.00%, and its revenue ttm is $26.53 Million , which makes it $0.73 revenue per share.

Of the last four earnings reports from Aquestive Therapeutics Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.42 for the next earnings report. Aquestive Therapeutics Inc.’s next earnings report date is 03rd Aug 2021.

The consensus rating of Wall Street analysts for Aquestive Therapeutics Inc. is Strong Buy (1), with a target price of $17, which is +374.86% compared to the current price. The earnings rating for Aquestive Therapeutics Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Aquestive Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Aquestive Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 18.96, ATR14 : 0.22, CCI20 : -29.18, Chaikin Money Flow : -0.23, MACD : -0.08, Money Flow Index : 50.15, ROC : 1.99, RSI : 44.46, STOCH (14,3) : 47.37, STOCH RSI : 0.64, UO : 52.18, Williams %R : -52.63), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Aquestive Therapeutics Inc. in the last 12-months were: A. Mark Schobel (Sold 75 792 shares of value $501 398 ), John T. Maxwell (Sold 3 000 shares of value $24 000 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (100.00 %)
3 (100.00 %)
3 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Aquestive Therapeutics Inc.

Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. The product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS). Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, and Zuplenz. The products pipeline includes Exservan Oral Film, Libervant Buccal Film, AQST-119, AQST-108, and AQST-305.

CEO: Keith J. Kendall

Telephone: +1 908 941-1900

Address: 30 Technology Drive, Warren 07059, NJ, US

Number of employees: 232

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

0%100%

Bearish Bullish

50%50%

Bearish Bullish

60%40%

Bearish Bullish

49%51%

News

Stocktwits